Zelboraf and Coma - a phase IV clinical study of FDA data
Summary:
Coma is reported as a side effect among people who take Zelboraf (vemurafenib), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Cotellic, and have Malignant melanoma.
The phase IV clinical study analyzes which people have Coma when taking Zelboraf. It is created by eHealthMe based on reports of 8,381 people who have side effects when taking Zelboraf from the FDA, and is updated regularly.
What is Zelboraf?
Zelboraf has active ingredients of vemurafenib. eHealthMe is studying from 8,392 Zelboraf users. Check the latest studies of Zelboraf.
What is Coma?
Coma (state of unconsciousness lasting more than six hours) is found to be associated with 2,822 drugs and 3,206 conditions by eHealthMe. Check the latest studies of Coma.
8,381 people reported to have side effects when taking Zelboraf.
Among them, 7 people (0.08%) have Coma.

Among these 7 people:
How long have people been on Zelboraf when they have Coma? *
- < 1 month: 0.0 %
- 1 - 6 months: 100 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
What is the gender of people who have Coma when taking Zelboraf? *
- female: 57.14 %
- male: 42.86 %
What is the age of people who have Coma when taking Zelboraf? *
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 33.33 %
- 50-59: 0.0 %
- 60+: 66.67 %
What are other drugs people take besides Zelboraf? *
- Ramipril: 2 people, 28.57%
- Cotellic: 2 people, 28.57%
- Tecentriq: 1 person, 14.29%
- Simvastatin: 1 person, 14.29%
- Mometasone Furoate: 1 person, 14.29%
- Metoprolol Tartrate: 1 person, 14.29%
- Metformin: 1 person, 14.29%
- Glyburide: 1 person, 14.29%
- Crestor: 1 person, 14.29%
- Celebrex: 1 person, 14.29%
What are other side effects people have besides Coma? *
- Death: 2 people, 28.57%
- Vascular Occlusion (sudden blockage of a blood vessel, usually with a clot): 1 person, 14.29%
- Swelling: 1 person, 14.29%
- Brain Oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain): 1 person, 14.29%
- Cardiac Arrest: 1 person, 14.29%
- Dehydration (dryness resulting from the removal of water): 1 person, 14.29%
- Diabetic Ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies): 1 person, 14.29%
- Diarrhea: 1 person, 14.29%
- Dyspnea (difficult or laboured breathing): 1 person, 14.29%
- Escherichia Sepsis (bacterial infection by escherichia coli): 1 person, 14.29%
What are the existing conditions these people have? *
- Malignant Melanoma (skin cancer rises from melancytes): 4 people, 57.14%
- Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 14.29%
- High Blood Pressure: 1 person, 14.29%
- Back Pain: 1 person, 14.29%
* Approximation only. Some reports may have incomplete information.
Do you take Zelboraf and have Coma?
- Check whether Coma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Zelboraf:
- Zelboraf (8,392 reports)
Coma treatments and more:
- Coma (57,420 reports)
How severe was Coma and when was it recovered:
Expand to all the drugs that have ingredients of vemurafenib:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Zelboraf:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Coma:
- Coma (2,822 drugs)
Browse all the conditions that are associated with Coma:
- Coma (3,206 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on vemurafenib (the active ingredients of Zelboraf) and Zelboraf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Myrbetriq and Gastrooesophageal Reflux Disease for Women aged 50-59 - a second ago
- Myrbetriq and Gastro-Oesophageal Reflux Disease for Women aged 50-59 - a second ago
- Myrbetriq and Reflux for Women aged 50-59 - a second ago
- Myrbetriq and Heartburn for Women aged 50-59 - 2 seconds ago
- Myrbetriq and Non-Cardiac Chest Pain for Women aged 50-59 - 2 seconds ago
- Myrbetriq and Gerds for Women aged 50-59 - 3 seconds ago
- Myrbetriq and Acid Reflux for Women aged 50-59 - 3 seconds ago
- Myrbetriq and Reflux Esophagitis for Women aged 50-59 - 4 seconds ago
- Myrbetriq and Pyrosis for Women aged 50-59 - 4 seconds ago
- Myrbetriq and Peptic Esophagitis for Women aged 50-59 - 4 seconds ago